$ROIV Income Statement | Understand Stock

$ROIV

$36.54 +$0.49 (1.36%) Close

$ROIV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Mar 31, 2026	FY2024 12 months to Mar 31, 2025	FY2023 12 months to Mar 31, 2024	FY2022 12 months to Mar 31, 2023	FY2021 12 months to Mar 31, 2022
Revenue
Product revenue, net
License, milestone and other revenue
Total revenue
Operating expenses:
Cost of revenues
Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)
Acquired in-process research and development
Selling, general and administrative (includes $164,841 and $186,603 of share-based compensation expense for the years ended March 31, 2024 and 2023, respectively)
General and administrative (includes $298,297, $239,505, and $154,873 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)
Total operating expenses
Gain on sale of Telavant net assets
Gain on litigation settlement
(Loss) income from operations
Change in fair value of investments
Gain on sale of investment
Change in fair value of debt and liability instruments
Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity
Gain on termination of Sumitomo Options
Change in fair value of liability instruments
Gain on deconsolidation of subsidiaries
Interest expense
Interest income
Other (income) expense, net
(Loss) income from continuing operations before income taxes
Income tax expense
(Loss) income from continuing operations, net of tax
Income (loss) from discontinued operations, net of tax
Net (loss) income
Net loss attributable to noncontrolling interests
Net (loss) income attributable to Roivant Sciences Ltd.
Net loss per common share—basic and diluted
Weighted average shares outstanding—basic and diluted
Net (loss) income per common share, basic:
(Loss) income from continuing operations, net of tax (in dollars per share)
Income (loss) from discontinued operations, net of tax (in dollars per share)
Net (loss) income (in dollars per share)
Net (loss) income per common share, diluted:
(Loss) income from continuing operations, net of tax (in dollars per share)
Income (loss) from discontinued operations, net of tax (in dollars per share)
Net (loss) income (in dollars per share)
Weighted average shares outstanding:
Basic (in shares)
Diluted (in shares)
Amounts attributable to Roivant Sciences Ltd.:
(Loss) income from continuing operations, net of tax
Income (loss) from discontinued operations, net of tax

Comments